Study identifies new marker to find patients with advanced prostate cancer more likely to benefit from combination immunotherapy
Patients with metastatic castration-resistant prostate cancer who do not benefit from chemotherapy need more effective treatment options
Phase 2 CheckMate 650 trial found ipilimumab plus nivolumab durable and clinically meaningful responses in a subset of patients
Through capabilities of the James P. Allison Institute, researchers identified a signature associated with prolonged overall survival, helping to find those most likely to benefit...
